BENIGN PROSTATIC HYPERPLASIA: COUNTING THE COST OF ITS MANAGEMENT

被引:28
作者
Kirby, Roger S. [1 ]
Kirby, Mike [1 ]
Fitzpatrick, John M. [2 ]
机构
[1] Prostate Ctr, London W1G 8GT, England
[2] Mater Misericordiae Univ Hosp, Dublin 7, Ireland
关键词
URINARY-TRACT SYMPTOMS; COMBINATION THERAPY; PRIMARY-CARE; DUTASTERIDE; MEN;
D O I
10.1111/j.1464-410X.2010.09274.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:901 / 902
页数:2
相关论文
共 12 条
  • [1] Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride
    Barkin, J
    Guimaraes, M
    Jacobi, G
    Pushkar, D
    Taylor, S
    van Vierssen Trip, OB
    [J]. EUROPEAN UROLOGY, 2003, 44 (04) : 461 - 466
  • [2] ECONOMIC BURDEN OF TREATED BENIGN PROSTATIC HYPERPLASIA IN THE UNITED-KINGDOM
    DRUMMOND, MF
    MCGUIRE, AJ
    BLACK, NA
    PETTICREW, M
    MCPHERSON, CK
    [J]. BRITISH JOURNAL OF UROLOGY, 1993, 71 (03): : 290 - 296
  • [3] Kirby R.S., 1995, J ROY SOC MED, V88, P284
  • [4] FACILITATING THE MEDICAL MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA IN PRIMARY CARE
    Kirby, Roger
    Kirby, Michael
    Fitzpatrick, John
    [J]. BJU INTERNATIONAL, 2009, 104 (06) : 751 - 753
  • [5] KIRBY RS, 1995, SHARED CARE PROSTATI
  • [6] The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    McConnell, JD
    Roehrborn, CG
    Bautista, OM
    Andriole, GL
    Dixon, CM
    Kusek, JW
    Lepor, H
    McVary, KT
    Nyberg, LM
    Clarke, HS
    Crawford, ED
    Diokno, A
    Foley, JP
    Foster, HE
    Jacobs, SC
    Kaplan, SA
    Kreder, KJ
    Lieber, MM
    Lucia, MS
    Miller, GJ
    Menon, M
    Milam, DF
    Ramsdell, JW
    Schenkman, NS
    Slawin, KM
    Smith, JA
    Kusek, JW
    Nyberg, LM
    Briggs, JP
    McConnell, JD
    Crawford, ED
    Homan, K
    Donohue, R
    Parker, D
    Easterday, K
    Robertson, K
    Kaplan, S
    Wentland, M
    Hardy, L
    Roehrborn, C
    Ahrens, A
    McConnell, J
    Hall, D
    Cutts, D
    Carter, S
    Waldrep, K
    Schenkman, N
    Sanetrik, K
    Sihelnik, S
    Zorn, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) : 2387 - 2398
  • [7] Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia
    Roehrborn, CG
    Marks, LS
    Fenter, T
    Freedman, S
    Tuttle, J
    Gittleman, M
    Morrill, B
    Wolford, ET
    [J]. UROLOGY, 2004, 63 (04) : 709 - 715
  • [8] The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
    Roehrborn, Claus G.
    Siami, Paul
    Barkin, Jack
    Damiao, Ronaldo
    Major-Walker, Kim
    Morrill, Betsy
    Montorsi, Francesco
    [J]. JOURNAL OF UROLOGY, 2008, 179 (02) : 616 - 621
  • [9] Guideline for the primary care management of male lower urinary tract symptoms
    Speakman, MJ
    Kirby, RS
    Joyce, A
    Abrams, P
    Pocock, R
    [J]. BJU INTERNATIONAL, 2004, 93 (07) : 985 - 990
  • [10] Tanguay S, 2009, CUAJ-CAN UROL ASSOC, V3, pS92